227 related articles for article (PubMed ID: 11837797)
1. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
Desnick RJ; Banikazemi M; Wasserstein M
Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
[TBL] [Abstract][Full Text] [Related]
3. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.
Shimohata H; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2020 Aug; 9(3):237-242. PubMed ID: 32189245
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
5. Renal complications of Fabry disease.
Basic-Jukic N; Kes P; Coric M; Basic-Kes V
Curr Pharm Des; 2013; 19(33):6046-50. PubMed ID: 23448456
[TBL] [Abstract][Full Text] [Related]
6. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease.
Germain DP
Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
[TBL] [Abstract][Full Text] [Related]
8. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
9. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
Germain DP
J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
[TBL] [Abstract][Full Text] [Related]
10. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
11. Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy.
Desnick RJ; Wasserstein MP; Banikazemi M
Contrib Nephrol; 2001; (136):174-92. PubMed ID: 11688379
[No Abstract] [Full Text] [Related]
12. Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry disease.
Sessa A; Meroni M; Battini G; Righetti M; Mignani R
Semin Nephrol; 2004 Sep; 24(5):532-6. PubMed ID: 15490423
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
14. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
[TBL] [Abstract][Full Text] [Related]
15. [Current management of Fabry disease].
Cochat P; Liutkus A; Dubourg L; Levade T
Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
[TBL] [Abstract][Full Text] [Related]
17. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
18. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
19. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
Chen Z; Yin B; Jiao J; Ye T
BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
[TBL] [Abstract][Full Text] [Related]
20. Renal manifestations in Fabry disease and therapeutic options.
Torra R
Kidney Int Suppl; 2008 Dec; (111):S29-32. PubMed ID: 19039306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
